Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

A Comparative Study on the Efficacy of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms: a Randomized Controlled Trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06803030

Enrollment

189

Registered

2025-01-31

Start date

2025-08-30

Completion date

2026-12-31

Last updated

2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ureteral Stent-Related Symptom

Keywords

Mirabegron, Tamsulosin, Solifenacin

Brief summary

A comparative study on the efficacy of Tamsulosin, Solifenacin and Mirabegron in alleviating ureteral stent-related symptoms: a randomized controlled trial.

Detailed description

Ureteral stent related symptoms can be a major issue in patient undergoing stent placement after any procedure such as- complains of pain, urinary symptoms, sex related and work related and other symptoms. These symptoms can be alleviated with use of drugs such as Tamsulosin, Solifenacin and Mirabegron. Patient recruited in each arm of the study will have their stent related symptoms scoring done using a validated outcome assessment tool to measure the ureteral stent-related symptoms, Ureteral Stent Symptom Questionnaire (USSQ) on day 1, day 7 and day 14 after the stent placement.

Interventions

DRUGTamsulosin Hydrochloride 0.4 mg

placement of ureteral stents followed by Cap. Tamsulosin 0.4 mg once daily

DRUGSolifenacin Succinate 5 mg

placement of ureteral stents followed by Tab. Solifenacin 5 mg once daily

DRUGMirabegron 25 mg

placement of ureteral stents followed by Tab. Mirabegron 25 mg once daily

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

• Eligible participants were adult patients (aged 19-80 years) who underwent unilateral retrograde rigid ureteroscopy (URS) or retrograde intrarenal surgery (RIRS) with planned ureteric stent insertion for urinary tract stones

Exclusion criteria

* Concomitant use of a-blockers, anticholinergics, corticosteroids, calcium channel blockers, and analgesics * Undergoing percutaneous nephrolithotomy, open ureteric surgery or laparoscopic ureteric surgery, including ureterolithotomy * Neurogenic bladder, Over Active Bladder (OAB) syndrome, and neurological and psychiatric diseases * Preoperative febrile Urinary Tract Infection (UTI) * Pregnancy or breastfeeding; * A single kidney * Moderate or severe cardiovascular or cerebrovascular disease * Hepatic dysfunction * History of pelvic surgery or irradiation * History of bladder or prostate surgery * Other acute medical conditions (including acute pancreatitis, acute gastroenteritis, musculoskeletal disorders) that might influence the Ureteral Stent Symptom Questionnaire(USSQ) pain score * Allergy to any medication

Design outcomes

Primary

Measure	Time frame	Description
alleviating Ureteral stent related symptoms	2 weeks	mitigating the ureteric stent related symptoms using structured questionnaire

Secondary

Measure	Time frame	Description
early removal of ureteral stent	before 2 weeks	early removal of stent due to stent migration, fever, urosepsis

Countries

Nepal

Contacts

Primary ContactBaikuntha Adhikari, MCh

baikadhe@gmail.com+977 9849896780

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026